Projects

RNDr. Zuzana Kozovská, PhD.
principal investigator

International

Current
  • International networking on in vitro colon models simulating gut microbiota mediated interactions
    Program: COST
    Duration: 9. 10. 2024 – 8. 10. 2028
Finished
  • Targeted combination therapy of colon cancer with therapeutic gene/drug loaded novel dendritic nanocarriers
    Program: Bilateral - other
    Duration: 3. 9. 2018 – 30. 11. 2022

National

Current
  • Identification of novel biomarkers linked to the relapse of metastatic colorectal cancer after metastasectomy
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Mutations associated with Wolfram syndrome: alternative signaling pathways for calcium and mitochondrial physiology
    Program: SRDA
    Duration: 1. 7. 2022 – 30. 6. 2026
  • Verification of clinically relevant biomarkers for the stratification of CRC patients by molecular and bioinformatic methods.
    Program: VEGA
    Duration: 1. 1. 2022 – 31. 12. 2025
Finished
  • Exosomes secreted by cancer cells of digestive organs, their characterization and modification by the CRISPR/Cas9 system for the aim of use in therapy
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Development of patients derived xenografts models and their utilization for personalized treatment of uveal melanoma
    Program: VEGA
    Duration: 1. 1. 2021 – 31. 12. 2024
  • Identification of chemoresistant cell populations with metastatic potential in colorectal carcinoma
    Program: VEGA
    Duration: 1. 1. 2019 – 31. 12. 2022
  • Markers overlapping chemoresistance and metastatic potential in colorectal cancer - aldehyde dehydrogenase and its clinical relevance
    Program: Other projects
    Duration: 1. 11. 2019 – 31. 12. 2022
  • TArgetiNg Dna mEthylation by epigenetic editing and its implementation into personalised diagnostics and therapy of uveal Melanoma
    Program: SRDA
    Duration: 1. 8. 2018 – 31. 12. 2022
  • Mechanism of the mesenchymal stromal cell-induced tolerance to antitumor treatment and targeted therapeutic intervention in the breast cancer cells
    Program: SRDA
    Duration: 1. 7. 2017 – 31. 12. 2021
  • Therapeutic targeting of cancer stem cell markers circumventing cisplatin resistance in testicular germ cell tumors
    Program: Other projects
    Duration: 1. 12. 2018 – 31. 12. 2020
  • The role of ALDH1 in chemoresistance of cancer cells
    Program: VEGA
    Duration: 1. 1. 2017 – 31. 12. 2020
  • Role of Stress Response Induced in Mesenchymal Stromal Cells in Extrinsic Drug Resistance of Human Tumor Cells
    Program: VEGA
    Duration: 1. 1. 2015 – 31. 12. 2018
  • Mechanisms of interactions and bystander effect mediated by mesenchymal stromal cells expressing prodrug-converting genes on tumour stem cells
    Program: SRDA
    Duration: 1. 10. 2013 – 30. 9. 2017
  • Cytotoxic Effect of Engineered Mesenchymal Stromal Cells on Human Chemoresistant Tumour Cells and Cancer Stem Cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Reversion of chemoresistance of human cancer stem cells
    Program: VEGA
    Duration: 1. 1. 2013 – 31. 12. 2016
  • Targeted Augmented Cellular Therapy against Tumor Initiating and Chemoresistant Cells
    Program: SRDA
    Duration: 1. 7. 2012 – 31. 12. 2015
  • Chemoresistance abrogation in human cancer stem cells by inhibition of ALDH1A1 enzyme
    Program: Other projects
    Duration: 1. 7. 2012 – 30. 6. 2013
  • Study of interactions between tumour cells and mesenchymal stem cells carrying suicide genes.
    Program: VEGA
    Duration: 1. 1. 2010 – 31. 12. 2012
Employees